FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558857105> ?p ?o ?g. }

• W2558857105 abstract "Abstract Abstract 3292 Patients with refractory immune thrombocytopenia (ITP) have limited therapeutic options, with morbidity and mortality as often from infection as from bleeding. Thrombopoietin (TPO) mimetics allow an increase in the platelet count without causing immunosuppression. These agents may be especially useful in patients with secondary forms of ITP. We report three patients treated with TPO agonists for ITP post Allogeneic Stem Cell Transplants (SCT). Patient 1: MC, 37yrs, developed refractory ITP after a myeloablative allogeneic SCT for Accelerated Phase CML. He was unresponsive to standard treatments (figure 1a), requiring platelet transfusions 3x weekly for active bleeding. He started Eltrombopag 50mg/day in July 2009. He had a clinically significant increase in his platelet count (supported count increased to 40) so platelet transfusions were reduced to 2x weekly. Eltrombopag was increased to 75mg in November with a subsequent platelet increase to 90 and by December 2009 he was platelet independent, maintaining a platelet count 90–120 on Eltrombopag alone, 25mg/day, 5 days week. Patient 2: BT, 4yrs(12kg), underwent a myeloablative allogeneic PBSCT in September 2009 for JIA/HLH. She became thrombocytopenic in June 2010, presumed to be ITP. She had no response to prednisolone or rituximab and a only a minimal response to IVIG; requiring platelets 1x weekly. She started Eltrombopag 7mg OD in November 2010, escalated to 12mg by February 2011. This had a synergistic effect with IVIG and she became platelet independent after one month of Eltrombopag and IVIG, maintaining platelet counts 50–200 (figure1b). Patient 3: MG, 62yrs, underwent a reduced intensity allogeneic SCT in March 2010 for stage 3 Sezary syndrome. Post SCT he developed pancytopenia associated with EBV reactivation. He received daily GCSF, regular blood and weekly platelet transfusions. In July he developed GI bleeding from HSV colitis and his platelet transfusion requirements increased to alternate days. In October 2010 he was started on Romiplostim 250mcg, increased to 350mcg weekly, erythropoetin and GCSF. He had a clinically significant rise in his platelet counts and a reduction in his platelet requirements to 1x weekly within weeks of starting romiplostim. By December he was platelet independent, with counts persistently over 50, and romiplostim was stopped (figure1c). All three patients remain in remission at the time of submission of the abstract. Immune cytopenias are well-recognised post myeloablative allografts occurring in 5–37% of SCT recipients. The occurrence of ITP in SCT recipients has been reported, in which GVHD or the production of anti-platelet alloantibodies of recipient origin was considered to play major roles. Although small numbers, these case studies show efficacy of thrombopoietic agents (recently licensed for use in chronic ITP) in patients with thrombocytopenia post SCT refractory to standard therapies, with an early reduction and subsequent cessation in platelet transfusion requirements in all three patients. The lack of immune suppression with these agents may be particularly relevant in patients post SCT, in whom immune reconstitution is vital not only in preventing infections, but also in preventing rejection of the graft and in establishing a graft versus leukaemia effect. Given that TPO receptors are present on haematopoietic stem cells at all stages of development and that TPO provides a growth factor for stem cells, the use of these agents in patients treated for leukaemia requires caution. There was no evidence of progression of disease in these patients and TPO agents were only required for a period of time (patient 3 is off therapy and the others only receive minimal doses). Formal evaluation of these agents in allogeneic SCT is warranted. Disclosures: Cooper: GSK: Honoraria; Amgen: Honoraria." @default.
• W2558857105 created "2016-12-08" @default.
• W2558857105 creator A5008779503 @default.
• W2558857105 creator A5018046100 @default.
• W2558857105 creator A5026334708 @default.
• W2558857105 creator A5061463272 @default.
• W2558857105 creator A5064462739 @default.
• W2558857105 creator A5064955144 @default.
• W2558857105 creator A5074115908 @default.
• W2558857105 creator A5089214570 @default.
• W2558857105 date "2011-11-18" @default.
• W2558857105 modified "2023-10-01" @default.
• W2558857105 title "Thrombopoietic Agonists Show Efficacy in ITP Related to Allogeneic Stem Cell Transplantation," @default.
• W2558857105 doi "https://doi.org/10.1182/blood.v118.21.3292.3292" @default.
• W2558857105 hasPublicationYear "2011" @default.
• W2558857105 type Work @default.
• W2558857105 sameAs 2558857105 @default.
• W2558857105 citedByCount "1" @default.
• W2558857105 countsByYear W25588571052019 @default.
• W2558857105 crossrefType "journal-article" @default.
• W2558857105 hasAuthorship W2558857105A5008779503 @default.
• W2558857105 hasAuthorship W2558857105A5018046100 @default.
• W2558857105 hasAuthorship W2558857105A5026334708 @default.
• W2558857105 hasAuthorship W2558857105A5061463272 @default.
• W2558857105 hasAuthorship W2558857105A5064462739 @default.
• W2558857105 hasAuthorship W2558857105A5064955144 @default.
• W2558857105 hasAuthorship W2558857105A5074115908 @default.
• W2558857105 hasAuthorship W2558857105A5089214570 @default.
• W2558857105 hasConcept C109159458 @default.
• W2558857105 hasConcept C121332964 @default.
• W2558857105 hasConcept C126322002 @default.
• W2558857105 hasConcept C141071460 @default.
• W2558857105 hasConcept C142424586 @default.
• W2558857105 hasConcept C2776689292 @default.
• W2558857105 hasConcept C2776715498 @default.
• W2558857105 hasConcept C2776915898 @default.
• W2558857105 hasConcept C2777863708 @default.
• W2558857105 hasConcept C2779338263 @default.
• W2558857105 hasConcept C2780588981 @default.
• W2558857105 hasConcept C2780653079 @default.
• W2558857105 hasConcept C28328180 @default.
• W2558857105 hasConcept C2911091166 @default.
• W2558857105 hasConcept C2993327898 @default.
• W2558857105 hasConcept C54355233 @default.
• W2558857105 hasConcept C71924100 @default.
• W2558857105 hasConcept C86803240 @default.
• W2558857105 hasConcept C87355193 @default.
• W2558857105 hasConcept C89560881 @default.
• W2558857105 hasConcept C90924648 @default.
• W2558857105 hasConceptScore W2558857105C109159458 @default.
• W2558857105 hasConceptScore W2558857105C121332964 @default.
• W2558857105 hasConceptScore W2558857105C126322002 @default.
• W2558857105 hasConceptScore W2558857105C141071460 @default.
• W2558857105 hasConceptScore W2558857105C142424586 @default.
• W2558857105 hasConceptScore W2558857105C2776689292 @default.
• W2558857105 hasConceptScore W2558857105C2776715498 @default.
• W2558857105 hasConceptScore W2558857105C2776915898 @default.
• W2558857105 hasConceptScore W2558857105C2777863708 @default.
• W2558857105 hasConceptScore W2558857105C2779338263 @default.
• W2558857105 hasConceptScore W2558857105C2780588981 @default.
• W2558857105 hasConceptScore W2558857105C2780653079 @default.
• W2558857105 hasConceptScore W2558857105C28328180 @default.
• W2558857105 hasConceptScore W2558857105C2911091166 @default.
• W2558857105 hasConceptScore W2558857105C2993327898 @default.
• W2558857105 hasConceptScore W2558857105C54355233 @default.
• W2558857105 hasConceptScore W2558857105C71924100 @default.
• W2558857105 hasConceptScore W2558857105C86803240 @default.
• W2558857105 hasConceptScore W2558857105C87355193 @default.
• W2558857105 hasConceptScore W2558857105C89560881 @default.
• W2558857105 hasConceptScore W2558857105C90924648 @default.
• W2558857105 hasLocation W25588571051 @default.
• W2558857105 hasOpenAccess W2558857105 @default.
• W2558857105 hasPrimaryLocation W25588571051 @default.
• W2558857105 hasRelatedWork W1476206338 @default.
• W2558857105 hasRelatedWork W1763430791 @default.
• W2558857105 hasRelatedWork W1940859004 @default.
• W2558857105 hasRelatedWork W1967149269 @default.
• W2558857105 hasRelatedWork W2048880885 @default.
• W2558857105 hasRelatedWork W211279767 @default.
• W2558857105 hasRelatedWork W2116694792 @default.
• W2558857105 hasRelatedWork W2270431576 @default.
• W2558857105 hasRelatedWork W2395887928 @default.
• W2558857105 hasRelatedWork W2523180857 @default.
• W2558857105 hasRelatedWork W2554712790 @default.
• W2558857105 hasRelatedWork W2557126671 @default.
• W2558857105 hasRelatedWork W2561898100 @default.
• W2558857105 hasRelatedWork W2562074606 @default.
• W2558857105 hasRelatedWork W2569540452 @default.
• W2558857105 hasRelatedWork W2967400485 @default.
• W2558857105 hasRelatedWork W2991620649 @default.
• W2558857105 hasRelatedWork W3046168531 @default.
• W2558857105 hasRelatedWork W3206222204 @default.
• W2558857105 hasRelatedWork W2528201489 @default.
• W2558857105 isParatext "false" @default.
• W2558857105 isRetracted "false" @default.
• W2558857105 magId "2558857105" @default.
• W2558857105 workType "article" @default.